K S Lawrence Wong1, Pierre Amarenco2, Gregory W Albers3, Hans Denison4, J Donald Easton5, Scott R Evans6, Peter Held4, Anders Himmelmann4, Scott E Kasner7, Mikael Knutsson4, Per Ladenvall4, Kazuo Minematsu8, Carlos A Molina9, Yongjun Wang10, S Claiborne Johnston11. 1. From the Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin (K.S.L.W.). 2. Department of Neurology and Stroke Centre, Bichat Hospital, Paris Diderot University, France (P.A.). 3. Stanford Stroke Center, Stanford University, CA (G.W.A.). 4. Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., M.K., P.L.). 5. Department of Neurology, University of California, San Francisco (J.D.E.). 6. Department of Biostatistics, Harvard University, Boston, MA (S.R.E.). 7. Department of Neurology, University of Pennsylvania, Philadelphia (S.E.K.). 8. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (K.M.). 9. Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (C.A.M.). 10. Department of Neurology, Beijing Tiantan Hospital, China (Y.W.). 11. Dean's Office, Dell Medical School, University of Texas at Austin (S.C.J.). clay.johnston@utexas.edu.
Abstract
BACKGROUND AND PURPOSE: SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization. METHODS: A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing patients with acute ischemic stroke (National Institutes of Health Stroke Scale score of ≤5) or transient ischemic attack (ABCD2 score of ≥4) to 90-day treatment with ticagrelor or aspirin. Patients in the prior-aspirin group had received any aspirin within the week before randomization. Primary end point was time to stroke, myocardial infarction, or death. Safety end point was PLATO (Study of Platelet Inhibition and Patient Outcomes) major bleeding. RESULTS: The 4232 patients in the prior-aspirin group were older, had more vascular risk factors, and vascular disease than the other patients. In the prior-aspirin group, the primary end point occurred in 138/2130 (6.5%) of patients on ticagrelor and in 177/2102 (8.3%) on aspirin (hazard ratio, 0.76; 95% confidence interval, 0.61-0.95; P=0.02); in patients with no prior-aspirin usage an event occurred in 304/4459 (6.9%) and 320/4508 (7.1%) on ticagrelor and aspirin, respectively (hazard ratio, 0.96; 95% confidence interval, 0.82-1.12; P=0.59). The treatment-by-prior-aspirin interaction was not statistically significant (P=0.10). In the prior-aspirin group, major bleeding occurred in 0.7% and 0.4% of patients on ticagrelor and aspirin, respectively (hazard ratio, 1.58; 95% confidence interval, 0.68-3.65; P=0.28). CONCLUSIONS: In this secondary analysis from SOCRATES, fewer primary end points occurred on ticagrelor treatment than on aspirin in patients receiving aspirin before randomization, but there was no significant treatment-by-prior-aspirin interaction. A new study will investigate the benefit-risk of combining ticagrelor and aspirin in patients with acute cerebral ischemia (URL: https://www.clinicaltrials.gov. Unique identifier: NCT03354429). CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01994720.
RCT Entities:
BACKGROUND AND PURPOSE: SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization. METHODS: A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing patients with acute ischemic stroke (National Institutes of Health Stroke Scale score of ≤5) or transient ischemic attack (ABCD2 score of ≥4) to 90-day treatment with ticagrelor or aspirin. Patients in the prior-aspirin group had received any aspirin within the week before randomization. Primary end point was time to stroke, myocardial infarction, or death. Safety end point was PLATO (Study of Platelet Inhibition and Patient Outcomes) major bleeding. RESULTS: The 4232 patients in the prior-aspirin group were older, had more vascular risk factors, and vascular disease than the other patients. In the prior-aspirin group, the primary end point occurred in 138/2130 (6.5%) of patients on ticagrelor and in 177/2102 (8.3%) on aspirin (hazard ratio, 0.76; 95% confidence interval, 0.61-0.95; P=0.02); in patients with no prior-aspirin usage an event occurred in 304/4459 (6.9%) and 320/4508 (7.1%) on ticagrelor and aspirin, respectively (hazard ratio, 0.96; 95% confidence interval, 0.82-1.12; P=0.59). The treatment-by-prior-aspirin interaction was not statistically significant (P=0.10). In the prior-aspirin group, major bleeding occurred in 0.7% and 0.4% of patients on ticagrelor and aspirin, respectively (hazard ratio, 1.58; 95% confidence interval, 0.68-3.65; P=0.28). CONCLUSIONS: In this secondary analysis from SOCRATES, fewer primary end points occurred on ticagrelor treatment than on aspirin in patients receiving aspirin before randomization, but there was no significant treatment-by-prior-aspirin interaction. A new study will investigate the benefit-risk of combining ticagrelor and aspirin in patients with acute cerebral ischemia (URL: https://www.clinicaltrials.gov. Unique identifier: NCT03354429). CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01994720.
Authors: S Claiborne Johnston; Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Peter Held; Jenny Jonasson; Kazuo Minematsu; Carlos A Molina; Lawrence K S Wong Journal: Int J Stroke Date: 2015-08-26 Impact factor: 5.266
Authors: S Claiborne Johnston; Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Jenny Jonasson; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; K S Lawrence Wong Journal: N Engl J Med Date: 2016-05-10 Impact factor: 91.245
Authors: Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Michael D Hill; Jenny Jonasson; Scott E Kasner; Per Ladenvall; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; K S Lawrence Wong; S Claiborne Johnston Journal: Lancet Neurol Date: 2017-02-23 Impact factor: 44.182
Authors: Marc P Bonaca; Shinya Goto; Deepak L Bhatt; P Gabriel Steg; Robert F Storey; Marc Cohen; Erica Goodrich; Laura Mauri; Ton Oude Ophuis; Mikhail Ruda; Jindřich Špinar; Ki-Bae Seung; Dayi Hu; Anthony J Dalby; Eva Jensen; Peter Held; David A Morrow; Eugene Braunwald; Marc S Sabatine Journal: Circulation Date: 2016-08-30 Impact factor: 29.690
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Holly Battenhouse; Robin Conwit; Catherine Dillon; Jordan Elm; Anne Lindblad; Lewis Morgenstern; Sharon N Poisson; Yuko Palesch Journal: Int J Stroke Date: 2013-08 Impact factor: 5.266
Authors: S Claiborne Johnston; Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang Journal: Int J Stroke Date: 2019-02-12 Impact factor: 5.266
Authors: Hamzah Khan; Reid Gallant; Shubha Jain; Mohammed Al-Omran; Charles De Mestral; Elisa Greco; Mark Wheatcroft; Ashraf Alazonni; Rawand Abdin; Margaret L Rand; Heyu Ni; Mohammad Qadura Journal: Medicina (Kaunas) Date: 2020-10-02 Impact factor: 2.430
Authors: Salvatore Santo Signorelli; Ingrid Platania; Salvatore Davide Tomasello; Marco Mangiafico; Giuliana Barcellona; Domenico Di Raimondo; Agostino Gaudio Journal: Int J Environ Res Public Health Date: 2020-08-12 Impact factor: 3.390